Revenue grew 6% year-over-year to $339 million, with all core platforms contributing to profitable growth and adjusted EPS up 4%. Guidance for FY27 was raised, reflecting strong plasma and MedSurg performance, robust cash flow, and continued innovation, while maintaining a disciplined outlook.Based…
Revenue grew 6% year-over-year to $339 million, with all core platforms contributing to profitable growth and adjusted EPS up 4%. Guidance for FY27 was raised, reflecting strong plasma and MedSurg performance, robust cash flow, and continued innovation, while maintaining a disciplined outlook.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
